<DOC>
	<DOCNO>NCT00022295</DOCNO>
	<brief_summary>RATIONALE : Phenoxodiol may stop growth tumor cell block enzymes necessary cancer cell growth . PURPOSE : Phase I trial study effectiveness phenoxodiol treat patient refractory solid tumor .</brief_summary>
	<brief_title>Phenoxodiol Treating Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose phenoxodiol patient refractory solid tumor . - Determine steady-state pharmacokinetics drug patient . - Determine tumor response patient treated drug . OUTLINE : This multicenter , dose-escalation study . Patients receive phenoxodiol IV continuously day 1-7 . Treatment repeat every 14 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos phenoxodiol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 4 week . PROJECTED ACCRUAL : Approximately 18-36 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor Refractory standard therapy OR No standard therapy exist No breast cancer No active CNS metastasis Known CNS metastases must previously treat radiotherapy surgery stable least 4 week prior study PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : Platelet count great 100,000/mm^3 WBC great 3,000/mm^3 Neutrophil count great 1,500/mm^3 Hemoglobin great 10 g/dL ( 9 g/dL woman ) Hepatic : Bilirubin le 1.2 mg/dL Transaminases great 3 time upper limit normal Renal : Creatinine great 1.4 mg/dL Other : No active infection No contraindication insertion vascular access device Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent systemic anticancer immunotherapy Chemotherapy : No concurrent systemic anticancer chemotherapy Endocrine therapy : No concurrent systemic anticancer hormonal therapy except luteinizing hormonereleasing hormone agonist antagonists Radiotherapy : See Disease Characteristics Concurrent localize radiotherapy control local disease complication allow Surgery : See Disease Characteristics Other : Recovered prior antineoplastic therapy At least 4 week since prior investigational agent No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>